Last reviewed · How we verify

DTaP-IPV/Hib Combined vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTaP-IPV/Hib Combined vaccine is a Combination vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children. Also known as: SP0204.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children.

At a glance

Generic nameDTaP-IPV/Hib Combined vaccine
Also known asSP0204
SponsorSanofi Pasteur, a Sanofi Company
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

The vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, inactivated poliovirus particles, and Haemophilus influenzae type b conjugate antigen. These components trigger both humoral (antibody) and cell-mediated immune responses, providing protection against these five serious bacterial and viral pathogens through active immunization.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-IPV/Hib Combined vaccine

What is DTaP-IPV/Hib Combined vaccine?

DTaP-IPV/Hib Combined vaccine is a Combination vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children.

How does DTaP-IPV/Hib Combined vaccine work?

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

What is DTaP-IPV/Hib Combined vaccine used for?

DTaP-IPV/Hib Combined vaccine is indicated for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children, Prevention of poliomyelitis in infants and children, Prevention of Haemophilus influenzae type b disease in infants and children.

Who makes DTaP-IPV/Hib Combined vaccine?

DTaP-IPV/Hib Combined vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is DTaP-IPV/Hib Combined vaccine also known as anything else?

DTaP-IPV/Hib Combined vaccine is also known as SP0204.

What drug class is DTaP-IPV/Hib Combined vaccine in?

DTaP-IPV/Hib Combined vaccine belongs to the Combination vaccine class. See all Combination vaccine drugs at /class/combination-vaccine.

What development phase is DTaP-IPV/Hib Combined vaccine in?

DTaP-IPV/Hib Combined vaccine is in Phase 3.

What are the side effects of DTaP-IPV/Hib Combined vaccine?

Common side effects of DTaP-IPV/Hib Combined vaccine include Injection site pain, redness, or swelling, Fever, Irritability or fussiness, Drowsiness, Loss of appetite.

Related